Page last updated: 2024-10-21

3,4-methylenedioxyamphetamine and Prostatic Neoplasms

3,4-methylenedioxyamphetamine has been researched along with Prostatic Neoplasms in 2 studies

3,4-Methylenedioxyamphetamine: An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally.

Prostatic Neoplasms: Tumors or cancer of the PROSTATE.

Research Excerpts

ExcerptRelevanceReference
"The hormonal treatment of advanced prostate cancer involves life disruptive side-effects, such as impotence, libido loss and bodily feminisation."1.32Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer. ( Morag, A; Navon, L, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Harrod, HL1
Navon, L1
Morag, A1

Other Studies

2 other studies available for 3,4-methylenedioxyamphetamine and Prostatic Neoplasms

ArticleYear
A piece of my mind. An essay on desire.
    JAMA, 2003, Feb-19, Volume: 289, Issue:7

    Topics: Attitude to Death; Attitude to Health; Erectile Dysfunction; Humans; Love; Male; Palliative Care; Pr

2003
Liminality as biographical disruption: unclassifiability following hormonal therapy for advanced prostate cancer.
    Social science & medicine (1982), 2004, Volume: 58, Issue:11

    Topics: Adaptation, Psychological; Aged; Aged, 80 and over; Feminization; Gender Identity; Hormone Replaceme

2004